Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
The FDA approved Pfizer's TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a front-line, chemotherapy-free maintenance treatment for adults with HER2+ metastatic breast cancer following induction therapy. The approval is based on the Phase 3 HER2CLIMB-05 trial, which showed median PFS of 24.9 months versus 16.3 months with placebo (HR 0.64, p<0.0001), a more than 50% improvement in median PFS. Safety was broadly consistent with TUKYSA's known profile, though the label carries a boxed warning for severe hepatotoxicity, including one fatal drug-induced liver injury case in the trial.
Key figures
- Drug Name
- TUKYSA (tucatinib)
- Phase Of Trial
- Phase 3
- Trial name
- HER2CLIMB-05
- Tukysa arm n
- 326
- Placebo arm n
- 328
- Pfs hazard ratio
- 0.64
- Risk reduction pct
- 35.9
- Median pfs tukysa arm months
- 24.9
- Median pfs placebo arm months
- 16.3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.